Their distinct role in the complex pathogenesis of AD, however, remains unknown.4 Somewhat consistently, data on the clinical efficacy of omalizumab, a recombinant humanized monoclonal antibody targeting the high‐affinity Fc receptor of IgE, are conflicting in AD, even when focusing on the subgroup of patients with high IgE levels. The gene discussed is IGHE; the disease is Alzheimer disease.